Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

HIV-1 Capsid Inhibitors: A Sword to Destroy the Virus
Xujie Zhang, Shujing Xu, Lin Sun, et al.
Future Medicinal Chemistry (2022) Vol. 14, Iss. 9, pp. 605-607
Closed Access | Times Cited: 12

Showing 12 citing articles:

Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Medicinal chemistry strategies in the discovery and optimization of HBV core protein allosteric modulators (2018–2022 update)
Xiaoyu Shao, Shujing Xu, Xufeng Wan, et al.
Chinese Chemical Letters (2023) Vol. 34, Iss. 11, pp. 108349-108349
Closed Access | Times Cited: 10
The discovery and design of novel HIV-1 capsid modulators and future perspectives
Dang Ding, Shujing Xu, Xujie Zhang, et al.
Expert Opinion on Drug Discovery (2022) Vol. 18, Iss. 1, pp. 5-12
Closed Access | Times Cited: 11
Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
Chunfu Wang, Haichang Huang, Kirsten Mallon, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 5
Open Access | Times Cited: 6
Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection
Tafadzwa Dzinamarira, Mazen Almehmadi, Ahad Amer Alsaiari, et al.
Medicina (2023) Vol. 59, Iss. 6, pp. 1041-1041
Open Access | Times Cited: 5
Design, synthesis, and mechanistic study of 2-piperazineone-bearing peptidomimetics as novel HIV capsid modulators
Xujie Zhang, Lin Sun, Shujing Xu, et al.
RSC Medicinal Chemistry (2023) Vol. 14, Iss. 7, pp. 1272-1295
Open Access | Times Cited: 4
Breaking the impossible: The evolutionary journey of lenacapavir, a long-acting anti-HIV drug
Kai Tang, Guochao Wei, Peng Zhan
Chinese Chemical Letters (2024), pp. 110500-110500
Closed Access | Times Cited: 1
The latest developments in the design and discovery of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV
Junyi Li, Bing Ye, Shenghua Gao, et al.
Expert Opinion on Drug Discovery (2024), pp. 1-18
Closed Access | Times Cited: 1
Design, Synthesis, and Mechanistic Study of 2-Pyridone-Bearing Phenylalanine Derivatives as Novel HIV Capsid Modulators
Xujie Zhang, Lin Sun, Shujing Xu, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7640-7640
Open Access | Times Cited: 7
Metabolite Identification of HIV-1 Capsid Modulators PF74 and 11L in Human Liver Microsomes
Shujing Xu, Lin Sun, Dang Ding, et al.
Metabolites (2022) Vol. 12, Iss. 8, pp. 752-752
Open Access | Times Cited: 4
Lenacapavir (Sunlenca): A Long‐acting HIV ‐1 Capsid Protein Inhibitor for Treating HIV Infection

(2024), pp. 77-96
Closed Access
Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatment of multidrug-resistant HIV infections
Dang Ding, Dazhou Shi, Shujing Xu, et al.
Elsevier eBooks (2024), pp. 341-349
Closed Access
Page 1

Scroll to top